BioPharma

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8...

Aragen, a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has announced the successful technology transfer and commercial-scale GMP manufacturing of the first batches of Daretabart, Renaissance Pharma’s lead therapeutic candidate for high-risk neuroblastoma. The milestone...

Nestlé Health Science and IdB Holding have officially announced a VOWST licensing agreement to develop and commercialize the oral therapy in Europe, subject to approval by the European Medicines Agency (EMA). This collaboration aims to expand European patient access...

The landscape of modern therapeutic development is being fundamentally reshaped by the precision of recombinant proteins driving biologics innovation. These highly engineered molecules serve as the foundational architecture for initial drug discovery, the creation of sophisticated high-throughput assay development, and the eventual transition into large-scale biologics manufacturing. By utilizing advanced protein expression platforms, the pharmaceutical industry can now produce specific, high-purity proteins that effectively mimic complex natural biological functions with extraordinary accuracy, ensuring that new treatments are both safe and potent for global distribution.

Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion...

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for...